Jeff Morhet is the President and CEO of the host corporate sponsor, InNexus Biotechnology, Inc. Mr. Morhet has vast experience in the pharmaceutical/biotechnology industry includes positions at Baxter Healthcare, Merck and AstraZeneca. His experience with pharmaceutical product development, manufacturing, regulatory affairs, product commercialization and working with the FDA for both drug and device applications, is extensive. Multiple times Mr. Morhet has been the corporate sponsor to the FDA for programs under development and has had a focus on cellular and intra-cellular anti-cancer drug development. Prior to InNexus he served as Vice President and General Manager of a NASDAQ-traded pharmaceutical company and refocused their long running cancer research, clinical development and pharmaceutical manufacturing programs. Mr. Morhet has launched multiple companies, including founding and growing Zila Biotechnolgy, Inc., a comprehensive research, development and licensing business. He is highly experienced in the areas of investor relations and corporate finance and has participated in raising over $100 Million in public offerings, venture capital, equities and mergers. Mr. Morhet also founded the life science networking group called ThirdBiotech (www.thirdbiotech.com). He is a graduate of Stephen F. Austin State University and attended the Executive MBA program at Arizona State University and other programs from Harvard Business School.

Thomas Kindt, Ph.D., Chief Scientific Officer of InNexus Biotechnology, Inc., was most recently Director of Intramural Research, NIAID, NIH, Bethesda, MD and Chief of Laboratory of Immunogenetics, NIAID, NIH and spent a year as Visiting Scientist, Analytical Immunochemistry Laboratory at the Institute Pasteur, Paris. Prior this he was with the Rockefeller University in New York and the City of Hope National Medical Center in Duarte, CA. Dr. Kindt has served on Advisory Boards and Committees of the Institute Pasteur, Tunis, Tunisia; Hematech LLC, Massachusetts; Institute for Medical Sciences, University of Tokyo; REDI Center, Singapore; NIH Facilities Working Group and Blue Ribbon Panel on Bioterrorism and implications for biomedical research. He has authored and co-authored 225 publications, two books and three patents; currently he is an active biomedical consultant, immunology textbook author and adjunct professor at the University of New Mexico’s Department of Biology.

Jur Strobos, Chief Medical Officer of InNexus Biotechnology, Inc., has extensive experience as Director of Policy Research in the office of the Commissioner of the Food and Drug Administration (FDA) and a diverse background in drug law, medical product development, and health care. Most recently, he was Vice President of Clinical Research and Regulatory Affairs for Medicis Pharmaceutical Corporation (NYSE: MRX). His prior medical background and four years of residency training in general surgery training enabled him to engage in policy development across the broad array of FDA activities from foods, devices, drugs, to biological products. His areas of expertise include food and drug law, clinical study design and good manufacturing practices. He has been the successful steward of multiple drugs and devices through the FDA and will be working closely with Dr. Thomas Kindt, InNexus' Chief Scientific Officer and previous Director of Intramural Research at the National Institute of Health. He has numerous publications and awards including the PHS Special Recognition Award, the FDA Award of Merit and two Commissioner Special Citations.

Wade Brooksby, Chief Financial Officer of InNexus Biotechnology, Inc., has held senior management positions in various companies ranging in size from small closely held companies to multi-billion dollar Fortune 100 NYSE firms. Mr. Brooksby has been involved in the development of licensing agreements of products and services in the USA, Canada, Mexico, Australia, South Africa, England, Germany, France, Spain and the Netherlands. For the past two years, Mr. Brooksby has been the CFO for a NASDAQ utility energy company. Previously he led the redesign, supervision and implementation of equipment, labor, customer relations and product development of a manufacturing plant for a NASDAQ pharmaceutical company. He has also been involved in the corporate governance for audit, compensation and executive committees for other public companies. Mr. Brooksby has served as an energy-marketing advisor to the Governor of Kentucky and on the Board of Directors of nine public and private companies and two not-for-profit organizations. He completed both his undergraduate and graduate studies in Accounting, Finance and Business Administration at Brigham Young University, located in Provo, Utah.